Background: Topical Brimonidine is approved by FDA for the treatment of rosacea-associated erythema. It has anti-inflammatory action, in additional to its vasoconstrictive activity, it preventes leucocyte recruitment via inhibition of transendothelial cells migration. Briominidine has been studied for many indications rather than rosacea with positive results. Objective: Review of the literature on the effectiveness of topical brimonidine in the treatment of various dermatological diseases. Methods: A comprehensive search was conducted in PubMed, Google Scholar, and Science Direct for information on Topical Brimonidine dermatological diseases. However, only the most current or comprehensive study from May 2011 to November 2022 was considered. The authors also assessed references from pertinent literature. Documents in languages other than English have been disregarded since there are not enough resources for translation. Unpublished manuscripts, oral presentations, conference abstracts, and dissertations were examples of papers that were not considered to be serious scientific research. Results: Mild, temporary skin-related adverse effects have been reported with 0.33 percent brimonidine topical gel. Maximum erythema reduction may occur 3–6 hours after application, while some patients report seeing results as early as 30 minutes. Conclusion: Combination therapy with brimonidine gel and other treatments for face papules and pustules is safe and does not enhance the risk of adverse outcomes.